跳至主要内容
临床试验/NCT04957368
NCT04957368已完成4 期

Sustained Mood Improvement With Laughing Gas Exposure: A Randomized Controlled Pilot Trial

Unity Health Toronto1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2021年11月3日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
40
试验地点
1
主要终点
Withdrawal rate

研究概览

简要总结

The purpose of the study is to investigate a short-term treatment option for major depressive disorders by administering nitrous oxide gas. At this time, the main purpose is to complete a feasibility study with 40 participants suffering from treatment-resistant depression. Participants will be randomized to (1) Study group: Nitrous oxide (inhaled) + solution of saline (injected) and the (2) Control group: Oxygen (inhaled) + Midazolam (injected) as an Active Placebo.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 18 to 65 years of age
  • Meeting Diagnostic and Statistical Manual for Mental Disorders (DSM-5) criteria for Major Depressive Disorder (MDD)
  • Current major depressive episode as confirmed by the Mini International Neuropsychiatric Interview (MINI) for DSM-5
  • Experiencing moderate to severe depressive episode, as defined by the Hamilton Depression Rating Scale (HAMD)>17
  • Failure of two trials of antidepressant therapy of adequate dose and duration, during the current depressive episode
  • For women of childbearing potential, use of highly effective or double-barrier methods of contraception. Abstinence is acceptable if it is the preferred and usual lifestyle of the female participant
  • Capacity to provide informed consent.
  • Exclusion criteria
  • Acute suicidality defined as score ≥3 on HAMD item 3
  • Major Depressive Episode in people with Bipolar Disorder
  • Current substance abuse or dependence and/or history of alcohol abuse or dependence within the past year
  • Current or lifetime history of schizophrenia or schizoaffective disorder
  • Current history of dissociative disorders
  • Known history of hypersensitivity or allergy to Nitrous Oxide, Midazolam or any ingredients in the study formulations
  • Contraindication to receiving nitrous oxide
  • Chronic cobalamin or folate deficiency
  • Contraindication to receiving the placebo midazolam
  • Use of centrally acting medicinal products, such as opioid agonists, morphine derivatives, benzodiazepines and/or other central nervous system depressants such as barbiturates and alcohol
  • Pregnancy or breastfeeding in female participants
  • Electroconvulsive therapy within the current depressive episode
  • Receiving ketamine treatment within the current depressive episode
  • Unwilling to maintain current antidepressant regimen.

排除标准

  • 未提供

研究组 & 干预措施

Nitrous Oxide + saline solution

Experimental

干预措施: Nitrous Oxide 99 % (Drug)

Oxygen + Midazolam

Active Comparator

干预措施: Oxygen + Midazolam (Drug)

结局指标

主要结局

Withdrawal rate

时间窗: 2 Years

Recruitment rate

时间窗: 2 Years

Recruitment rate

Adherence rate

时间窗: 2 Years

Feasibility

Frequency of adverse events

时间窗: 2 Years

Safety and tolerability

次要结局

  • Montgomery-Åsberg Depression Rating Scale (MADRAS) Score 0-60 (Higher scores represent higher depression). Measure changes in symptoms of depression(6 weeks)
  • Toronto Side Effects Scale (TSES) - 32 items (each item has a score 1-25; higher score means higher intensity). Measure adverse side effects from antidepressant treatment(6 weeks)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Sustained Mood Improvement With Laughing Gas... | 临床试验